Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Peter Gottlieb MD

Peter A. Gottlieb MD

Orr Family Endowed Chair in Adult Diabetes; Professor of Pediatrics and Medicine, Barbara Davis Center/University of Colorado School of Medicine, Aurora, Colorado

Dr. Peter Gottlieb is the Orr Family Endowed Chair in Adult Diabetes and a Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado School of Medicine. His research interests are in autoimmunity of Type 1 Diabetes and other endocrine disorders, the role of T and B lymphocytes in disease pathogenesis and clinical trial design. He is the Chair of the Collaborative Mechanistic Studies Panel for Type 1 Diabetes TrialNet.

Dr. Gottlieb has been involved in many clinical trials to prevent and reverse type 1 diabetes through NIH, industry and investigator-initiated studies. He co-founded ImmunoMolecular Therapeutics, Inc., a spinout from the University of Colorado to develop small molecule inhibitors of antigen presentation. He consults for several biotech and pharma companies and is a consultant to the JDRF T1D Fund.


Dr. Gottlieb reports the following:
  • Co-founder, CMO and shareholder in IM Therapeutics, Inc.
  • Grants/Research – NIH, Helmsley, JDRF, Nova Pharmaceuticals, Intrexon T1D Partners, Novartis, Imcyse, Provention Bio
  • Consultant – Provention Bio, Viacyte, Imcyse, JDRF T1D Fund